3 research outputs found
Platelet Inhibition, Endothelial Function, and Clinical Outcome in Patients Presenting With ST-Segment-Elevation Myocardial Infarction Randomized to Ticagrelor Versus Prasugrel Maintenance Therapy: Long-Term Follow-Up of the REDUCE-MVI Trial
Background Off-target properties of ticagrelor might reduce microvascular injury and improve clinical outcome in patients with ST-segment-elevation myocardial infarction. The REDUCE-MVI (Evaluation of Microvascular Injury in Revascularized Patients with ST-Segment-Elevation Myocardial Infarction Treated With Ticagrelor Versus Prasugrel) trial reported no benefit of ticagrelor regarding microvascular function at 1 month. We now present the follow-up data up to 1.5 years. Methods and Results We randomized 110 patients with ST-segment-elevation myocardial infarction to either ticagrelor 90Â mg twice daily or prasugrel 10Â mg once a day. Platelet inhibition and peripheral endothelial function measurements includi
Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology
Heart failure (HF) is growing to a modern epidemic and despite
advances in therapy, it still carries an ominous prognosis and a significant socioeconomic burden. Many novel agents that emerged as
promising HF drugs failed to improve residual morbidity and mortality.2,3 Since developing and testing new agents has become increasingly costly,4 the concept of repurposing existing drugs for new
indications has gained considerable importance.
Conceptually, comorbidities such as type 2 diabetes mellitus
(T2DM), obesity or chronic kidney disease, all highly prevalent in HF
populations, have shifted from being innocent bystanders to drivers
of HF. This applies especially to HF with preserved ejection fraction
(HFpEF), a phenotype that accounts for more than 50% of HF
patients and for which no effective therapy exists thus far.5,6 In particular, the prevalence of T2DM, thereby its combination with HF is
rapidly increasing, mainly due to the obesity epidemic.
Cardiovascular (CV) outcomes are addressed by an increasing
number of clinical studies in T2DM, mainly as safety endpoints for
anti-diabetic agents. Some of those drugs have beneficial CV effects
independent of their glucose-lowering action. Consequently, antidiabetic agents have gained interest for their potential repurposing in
HF treatment. In this context, the Translational Research Committee
of the Heart Failure Association (HFA) of the European Society of
Cardiology (ESC) organized a workshop on HF and T2DM, focusing
on the pathophysiological and therapeutic aspects of this relationship.
Here, we summarize the main points raised during this workshop,
providing an overview of current evidence and open issues
Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology
Heart failure (HF) is growing to a modern epidemic and despite
advances in therapy, it still carries an ominous prognosis and a significant socioeconomic burden. Many novel agents that emerged as
promising HF drugs failed to improve residual morbidity and mortality.2,3 Since developing and testing new agents has become increasingly costly,4 the concept of repurposing existing drugs for new
indications has gained considerable importance.
Conceptually, comorbidities such as type 2 diabetes mellitus
(T2DM), obesity or chronic kidney disease, all highly prevalent in HF
populations, have shifted from being innocent bystanders to drivers
of HF. This applies especially to HF with preserved ejection fraction
(HFpEF), a phenotype that accounts for more than 50% of HF
patients and for which no effective therapy exists thus far.5,6 In particular, the prevalence of T2DM, thereby its combination with HF is
rapidly increasing, mainly due to the obesity epidemic.
Cardiovascular (CV) outcomes are addressed by an increasing
number of clinical studies in T2DM, mainly as safety endpoints for
anti-diabetic agents. Some of those drugs have beneficial CV effects
independent of their glucose-lowering action. Consequently, antidiabetic agents have gained interest for their potential repurposing in
HF treatment. In this context, the Translational Research Committee
of the Heart Failure Association (HFA) of the European Society of
Cardiology (ESC) organized a workshop on HF and T2DM, focusing
on the pathophysiological and therapeutic aspects of this relationship.
Here, we summarize the main points raised during this workshop,
providing an overview of current evidence and open issues